| 廖斌 刘慧霞 周洪 罗函颖 李强翔.西格列汀对老年2 型糖尿病合并轻中度慢性心衰患者hs-CRP及NT-proBNP 的影响[J].现代生物医学进展英文版,2015,15(26):5059-5062. |
| 西格列汀对老年2 型糖尿病合并轻中度慢性心衰患者hs-CRP及NT-proBNP 的影响 |
| Effect of Sitagliptin on Peripheral SerumLevels about hs-CRP, NT-proBNPof elderly Patients who Suffer fromType 2 Diabetes with Mild to ModerateChronic Heart Failure |
| |
| DOI： |
| 中文关键词: 西格列汀 2 型糖尿病 慢性心衰 hs-CRP NT-proBNP |
| 英文关键词: Sitagliptin Type 2 diabetes Chronic heart failure Hs-CRP NT-proBNP |
| 基金项目:湖南省卫生厅科研计划课题( C2012-038)；湖南省高层次卫生人才"225" 工程培养项目资助 |
|
| Hits: 681 |
| Download times: 0 |
| 中文摘要: |
| 目的：探讨使用西格列汀对老年2 型糖尿病合并轻中度慢性心衰患者外周血超敏Ｃ 反应蛋白（high-sensitivity C-reactive
Protein，hs-CRP）、N- 端B型脑钠肽前体（N-terminal pro-B-type natriuretic peptide，NT-proBNP）的影响。方法：将我院90 例老年2
型糖尿病合并轻中度慢性心衰患者随机分成观察组和对照组分别46 例和44 例。两组患者均给予常规抗心衰治疗，对照组予以
格列吡嗪控释片降糖，观察组予以西格列汀口服降糖治疗。检测试验前后患者血清hs-CRP 及NT-proBNP 的水平，并常规检测血
压、血脂、糖化血红蛋白、血糖及肝肾功能等指标。结果：两组治疗后HbA1c 水平与治疗前比较均有下降，差异均有统计学意义
(P<0.05)；西格列汀组的hs-CRP、NT-proBNP水平治疗后分别下降至6.67± 0.85 mg/L，1412.27± 92.28 pg/mL，与治疗前比较差异
均有统计学意义(P<0.05)；治疗后西格列汀组的hs-CRP、NT-proBNP 水平与对照组比较差异有统计学意义(P<0.05)。结论：2型糖
尿病合并轻中度慢性心功能不全患者服用西格列汀除有效降糖外还能一定程度地降低hs-CRP和NT-proBNP水平，提示其潜在
改善心脏功能的作用。 |
| 英文摘要: |
| Objective:This study was designed to investigate the effection of Sitagliptin on peripheral serumlevels about high-sensitivity
C-reactive Protein(hs-CRP), N-terminal pro-B-type natriuretic peptide (NT-proBNP) of elderly patients who suffer fromtype 2 diabetes
with mild to moderate chronic heart failure.Methods:90 cases of our hospital elderly patients who suffer fromtype 2 diabetes with
mild to moderate chronic heart failure were randomly divided into two groups. The observation group contains 46 cases and the control
group is 44 cases, respectively. Two groups were applied with conventional heart failure treatments, the control group received glipizide,
while the observation group were given sitagliptin. The serum levels of hs-CRP and NT-proBNP were detected both before and after the
test, with routine tests of blood pressure, blood-lipids, glycated hemoglobin, glucose, hepatic and renal function and other indicators.Results:Compared with before treatments, the HbA1c levels of the two groups after treatment were decreased, the differences were statistically
significant (P<0.05); The serum levels of hs-CRP and NT-proBNP in sitagliptin group were decreased to 6.67± 0.85mg /L and
1412.27± 92.28 pg /mL after the treatments. The differences were both statistically significant (P<0.05) by comparing with the serum
levels before the treatments. After the treatments, the differences of serum levels of hs-CRP and NT-proBNP in the sitagliptin group was
statistically significant compared with control group (P<0.05).Conclusion:In type 2 diabetes patients with mild to moderate chronic heart
failure patients, taking Sitagliptin can decrease blood glucose effectively，meanwhile reduce the hs-CRP and NT-proBNP levels at some
extent, It can reveal that Sitagliptin may have the potential to improve cardiac function. |
|
View Full Text
View/Add Comment Download reader |
| Close |
